Adaptive Designs in Clinical Drug Development

Adaptive Designs are the future for clinical trials.

Adaptive Design techniques already have had notable successes in cutting the costs of clinical trials and times to market for drugs. But despite their phenomenal potential, uncertainty still remains as to appropriate implementation, best practice, and the regulatory framework. SMi's 2nd Annual conference on Adaptive Designs in Clinical Drug Development will showcase presentations from leaders in this exciting and profitable area, and provide the perfect environment to network with fellow delegates with an interest in the field.

This event will cover the realities of adaptive clinical trials; from looking at the technology and infrastructure needed, to choosing and applying the right model according to the aims of the trial; from potential pitfalls in implementation, to a number of examples from real clinical trials.

Key issues to be discussed will include:

• Focus on the latest technology and infrastructure for adaptive trials
• Learning and Confirming with adaptive trials
• Adaptive design in early phase drug development
• A closer look at some of the latest statistical models
• Numerous Case Studies from top pharmaceutical companies

**NEW TOP SPEAKERS CONFIRMED!**

• Richard Young, Director of Business Development, CMED Research
• Nitin Patel, Co-Founder, Chairman and CTO, Cytel
• Cyrus Mehta, President and Co-Founder, Cytel
• Bill Byrom, Vice President, Product Strategy, Clinphone

Confirmed Speakers:

• James Matcham, Biostatistics Director, Amgen
• Bruno Boulanger, Head, Exploratory Statistics, UCB Pharmaceuticals
• Alex Bajamonde, Director, Early & Business Development, DATA Group, Genentech
• Surya Mohanty, Senior Director, Biometrics and Clinical Informatics, Johnson and Johnson PRD
• Tom Parke, Head of Clinical Trials Solutions, Tessella
• Yu Shyr, Professor and Chief, Division of Cancer Biostatistics, Vanderbilt University
• Judith Quinlan, Director of Statistics, Biopharm CEDD, GSK
• Michael Borkowski, General Manager Of Clinical Technologies, United Biosource Corporation
• Francois Vandenhende, CEO, ClinBAY
• Melissa Spann, Research Scientist, Neuroscience statistics, Eli Lilly
• Alun Bedding, Biostatistics and Programming Development Partners, Drug Development Sciences, GSK
• Inna Perevoszkaya, Clinical Biostatistics, Merck & Co.
• Stuart Pocock, Medical Statistics Unit, London School of Hygiene and Tropical Medicine
• Rhian Jones, Clinical Pharmacy Coordinator I, Wyeth
• Steve Pascoe, Global Head, Respiratory/ Dermatology Profiling Exploratory Clinical Development, Novartis

This event is aimed at all those involved in implementing clinical trials, or associated statistical work. This includes those working in:

Biostatistics, Clinical R&D, Medical Affairs, Clinical Operations, Clinical Supplies, Data Management, Portfolio Management, and Regulatory Affairs